Earnings & Results
Light AI Narrows Q3 2026 Loss to $1.5 million and Says More Financing Is Needed Within 12 Months
By News Desk ·
Key takeaways
- Light AI reported an unaudited Q3 2026 net loss of $1.5 million, down from $5.6 million a year earlier.
- The company held $6.1 million in cash at September 30 and expects to need additional financing within 12 months.
- QuickScan development timelines have been affected by remediation, and John W. Meekison was appointed interim chair after two directors resigned.
Light AI Inc. (ALGO) reported an unaudited third-quarter 2026 net loss of $1.5 million, down from $5.6 million a year earlier, and said it expects to need additional financing within 12 months. TradingView carried the release, which was distributed by PR Newswire. Light AI is a Vancouver-based medical imaging software company that uses AI to analyze smartphone images to detect Strep A, COVID-19 and conjunctivitis without swabs or proprietary hardware.
Light AI's Cash and Nine-Month Loss
The company held $6.1 million in cash at September 30, compared with $6.5 million at December 31. Operating cash outflow was $5.2 million for the nine months. The nine-month net loss was $5.2 million, against $13.9 million in 2025.
Light AI said evidence gaps in the complete diagnostic system require further development and validation, and that QuickScan development timelines have been affected by remediation. Two directors resigned, and John W. Meekison was appointed interim chair.
Light AI's Funding and Trial Record
According to akta.pro company records, Light AI closed a US$5 million private placement led by MV Capital in June 2026 to fund ISO 13485/QMS audit completion and Health Canada registration submission. The same records list seven funding rounds on file and total funding of $40.3 million, with the last round dated May 21, 2026.
The records also show that in June 2026 Light AI initiated an FDA pivotal clinical trial for QuickScan Strep A as a Class II Software as a Medical Device, described as the gating milestone for US commercialization.
Light AI's Path to the Third Quarter
In June 2026, Light AI completed its quality management system audit and received ISO 13485:2016 and MDSAP certification from Intertek, supporting planned Health Canada submissions for QuickScan and QuickScan Strep A, Newswire reported. Also in June 2026, Light AI announced a company-funded field study in New Zealand with the National Hauora Coalition to evaluate the QuickScan Strep A platform in community and school settings, Newswire reported.
In August 2026, Light AI reported a second-quarter net loss of $1.6 million, down from $4 million a year earlier, Yahoo reported.
Light AI's QuickScan Remediation
Light AI said the remediation tied to evidence gaps in the complete diagnostic system has affected QuickScan development timelines, and the company expects additional financing over the next 12 months.